Novartis AG (NVS)
11 Mar 2014
|Market Cap (Mil.):||$224,643.00|
|Shares Outstanding (Mil.):||2,706.19|
ZURICH - Novartis drug Jakavi achieved its main goal in a late-stage trial for patients suffering from a rare blood cancer, putting it on track to become a potential blockbuster treatment with sales of $1 billion-plus.
ZURICH, March 7 - Novartis drug Jakavi achieved its main goal in a late-stage trial for patients suffering from a rare blood cancer, putting it on track to become a potential blockbuster treatment with sales of $1 billion-plus.
ZURICH, March 7 - Swiss drugmaker Novartis said on Friday a final stage test of Jakavi, used to treat patients with a rare blood cancer, had met its primary endpoint and improved two key measures of disease control in patients.
ROME - Italian prosecutors looking into allegations of collusion between Roche and Novartis over a cancer drug suspect the firms of possible fraud and manipulating the drugs market, judicial sources said on Thursday.
* Watchdog fined firms for collusion over cancer drug use
ROME, March 6 - Italian prosecutors looking into allegations of collusion between Roche and Novartis suspect possible market manipulation and aggravated fraud, judicial sources said on Thursday.
ZURICH/MILAN - Italy's antitrust authorities said Swiss drugmakers Novartis and Roche colluded to try to stop cancer drug Avastin being used to treat a serious eye disease, and fined the companies 182.5 million euros ($251 million).
* Rome prosecutors open a file on the companies - sources (Adds statement from Italian health ministry)
ROME, March 5 - Prosecutors in Rome have opened a file on Novartis and Roche after the Italian antitrust regulator fined the drug companies over alleged anti-competitive practices, judicial sources said on Wednesday.
ZURICH/MILAN - Italy's antitrust authorities said Novartis and Roche colluded to try and stop cancer drug Avastin being used to treat a serious eye disease, and fined the Swiss drugmakers 182.5 million euros ($251 million).
|Johnson & Johnson (JNJ.N)||$92.78||-0.71|
|Pfizer Inc. (PFE.N)||$32.07||-0.35|
|Merck & Co., Inc. (MRK.N)||$56.42||-0.27|
|Roche Holding Ltd. (ROG.VX)||CHF257.90||-2.40|
|Abbott Laboratories (ABT.N)||$39.55||-0.16|
|Sanofi SA (SASY.PA)||€72.78||-1.26|
|AstraZeneca plc (AZN.L)||3,974.71p||-43.50|
|GlaxoSmithKline plc (GSK.L)||1,649.50p||-24.50|
|Eli Lilly and Co (LLY.N)||$58.36||-0.07|
|Bristol-Myers Squibb Co (BMY.N)||$55.31||-0.52|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (NVS). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: Wright Reports
Provider: S&P Capital IQ – STARS Reports
Novartis AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Pechala's Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.